||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Real-Time news about Antisoma (London Stock Exchange): 0 recent articles
|jsbach123: Another month passes with no news - though today has been 'enlivened' by a further slump in share price|
|gazmat: "duncandisorderly - 8 Feb'11 - 17:29 - 5576 of 5578
For the life of me I can't understand why all you,"non holding idiots"spend hour upon hour clogging up these sites with your pointless arguments.P*ss off the lot of you and leave these sites to genuine holders."
I really don't believe anybody posts here unless there is an ulterior motive - PIs tilting at windmills in the hope of moving the share price to their advantage or paid posters doing their masters bidding in an effort to shift sentiment.|
|clubman: For sale sign goes up at Antisoma
Date: Tuesday 08 Feb 2011
The company, which saw its share price plummet at the end of January after it abandoned development of its leukaemia treatment drug AS1413, expects to cut the size of its workforce to a maximum of 10 by the end of March, and will announce some departures from the board of directors soon.
Workforce of 10 I have more domestic staff than that.
Goodnight Antisoma the curtain is falling ORA only want its listing, and maybe some desks and chairs.|
|christianf12: Who cares about the goodwill or intangibles when cash alone is worth 150% of the current share price and more?|
|the_doctor: yet potentially a blip here and you're already prancing around congratulating yourself.
If you'd actually shorted them and made a profit it'd be better, but you havent. In fact, the only share I'm aware of you trading recently out of the various ones we both watch, is SKP - where I suggested to you that it was due a bounce.... you rambled some daft nonsense about shares getting worse the lower a share price goes and got burnt when your stoploss got hit.|
|topinfo: 16:04, Monday 7 June 2010
LONDON (ShareCast) - Cancer drug developer Antisoma (LSE: ASM.L - news) is continuing its share price recovery following a buy recommendation from broker KBC Peel Hunt.
The broker believes that the upside in the shares could be considerable if there is positive news from two cancer drug trials over the next 12 months.
The AS1413 phase III study for secondary acute myeloid leukaemia is due to be published in the first half of 2011 and the phase IIb study of AS1411 for acute myeloid leukaemia and renal cell carcinoma should be reported on at around the same time.
A commercial partner for either drug could further boost the share price. The company's cash should last until late 2011.
|lancers: Moochy. Rab Capital saw value in Northern Rock and many people followed them - and lost the lot. Don't base your investment/speculations on the actions of others.
"We may wake up one morning and find it's share price has jumped to 25p".
And if Novartis withdraw all funding and the news is released pre open we may wake up one morning and find ASM's shareprice has crashed to 4p.|
|moochy: BVF Partners bought 29,715,992 shares now valued at about £2,377,2793 hence they value ASM. Surely they must see some sort of value in it or they wouldn't be risking this kind of money. They may be interested in the results of failed tests to see if:
1. There could be some other use for this drug (since it would be a shame to waste all this time and money to no avail).
2. They could find out where it's gone wrong and perhaps backtrack, and have a go at finding a solution to the problem.
3. ASM may posess the missing link for another drug that's being developped by one of their other investments.
Who knows? One thing for sure is that there is interst in ASM. All is not lost yet. We may wake up one morning and find it's share price has jumped to 25p.|
|lordchuffer: Look down this page,a US investment fund has just bought a 5% stake in the company.Interesting times ahead?
The clearout began at Antisoma, the stricken biotech, yesterday as its well-regarded chief operating officer left the company and its board.
Ursula Ney's departure is likely to be the first of many from Antisoma, which employs about 90 people, including 60 in its research department. The company has to make its remaining cash of £45 million stretch until the end of next year as it makes a last-ditch effort to achieve salvation by completing trials on two medicines.
It is believed that Antisoma will have to make a £280,000 termination payment to Dr Ney, who oversaw the development of medicines and was the company's second-highest earner, with salary and benefits of £406,000 - surpassed only by the £512,000 remuneration of Glyn Edwards, the chief executive. In total, the company's directors were paid £1.7 million, including pension payments, last year.
Antisoma, once regarded as one of UK biotechnology's brightest hopes, was plunged into disarray this week when it emerged that its most promising drug had performed poorly in large-scale clinical trials. The medicine, ASA404, a treatment for lung cancer developed in partnership with Novartis, the Swiss pharmaceutical group, had shown extremely promising results in earlier trials. It was supposed to work by cutting off the blood supply to the tumour and halting its growth.
Antisoma shares collapse after drug failure
Results of lung cancer drug's new trial send Antisoma's shares soaring
However, the plug was pulled early in the latest trial, suggesting that the treatment had little effect. Antisoma received $100 million (£65 million) from Novartis, but further payments depended on the success of the drug.
The company's hopes now rest with trials for AS1413, a treatment for secondary acute myeloid leukaemia, which will conclude in December, and AS1411, another myeloid leukaemia treatment. But even if they work well, the relative rarity of the disease means that the drugs will be far less lucrative than ASA404 would have been.
Daniel Elger, a spokesman for Antisoma, told The Times this week that the company would examine its cost base immediately, although few in the sector expected action to be quite so swift.
The company's market value fell by three quarters on Monday and it is now valued at about £50 million - barely more than its existing cash. Its shares rallied yesterday, climbing by 6.7 per cent to 8p.
There was some ground for optimism at the company yesterday after it emerged that a leading US biotech investment fund built a 5 per cent stake after the share price fall. Biotech Value Fund Partners bought 4.74 per cent of Antisoma's shares as their value plummeted after the announcement about ASA404.
Dr Ney, a former development director for Celltech, one of the sector's biggest success stories, had been with Antisoma for six years. She has also worked as chief executive of Charterhouse Therapeutics, the biotech minnow that was bought by York Pharma.
Samir Devani, analyst for Nomura Code, said: "It's a logical step to try to preserve as much capital as they can."
Barry Price, chairman of Antisoma, said: "Ursula has made an enormous contribution to Antisoma and its board. I would like to thank her for all she has done to build a world-class development team, and regret profoundly that she and other talented individuals are leaving because of the news we have received this week.|
It's nothing about being able to stand the heat - it's about being sensible and level headed and trying to get some answers.
At this rate the share price looks like it's heading straight back into the 20's
Do you have any ideas why the share price is starting to fall like a stone ?
i.e. why is everyone bailing out ?
Just check out the trades today ... virtually all sells.
Antisoma share price data is direct from the London Stock Exchange